Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

493 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization.
Pillinger MH, Bangalore S, Klein AB, Baumgartner S, Morlock R. Pillinger MH, et al. Among authors: baumgartner s. J Manag Care Spec Pharm. 2017 Jun;23(6):677-683. doi: 10.18553/jmcp.2017.23.6.677. J Manag Care Spec Pharm. 2017. PMID: 28530520 Free PMC article.
Klein is employed by AstraZeneca. At the time of this study, Baumgartner was employed by Ardea Biosciences, a wholly owned subsidiary of AstraZeneca and owns stock in AstraZeneca. Baumgartner and Morlock are consultants to Ardea Biosciences. Morlock reports consulti …
Klein is employed by AstraZeneca. At the time of this study, Baumgartner was employed by Ardea Biosciences, a wholly owned subsidiary …
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, Baumgartner S; RDEA594-111 Study Group. Fleischmann R, et al. Among authors: baumgartner s. Rheumatology (Oxford). 2014 Dec;53(12):2167-74. doi: 10.1093/rheumatology/ket487. Epub 2014 Feb 8. Rheumatology (Oxford). 2014. PMID: 24509406 Clinical Trial.
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F. Dalbeth N, et al. Among authors: baumgartner s. Arthritis Rheumatol. 2017 Sep;69(9):1903-1913. doi: 10.1002/art.40159. Epub 2017 Aug 4. Arthritis Rheumatol. 2017. PMID: 28597604 Free PMC article. Clinical Trial.
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA. Saag KG, et al. Among authors: baumgartner s. Arthritis Rheumatol. 2017 Jan;69(1):203-212. doi: 10.1002/art.39840. Arthritis Rheumatol. 2017. PMID: 27564409 Clinical Trial.
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
Fitz-Patrick D, Roberson K, Niwa K, Fujimura T, Mori K, Hall J, Yan X, Shen Z, Liu S, Ito Y, Baumgartner S. Fitz-Patrick D, et al. Among authors: baumgartner s. Mod Rheumatol. 2019 Nov;29(6):1042-1052. doi: 10.1080/14397595.2018.1538003. Epub 2018 Dec 12. Mod Rheumatol. 2019. PMID: 30334639 Free article. Clinical Trial.
493 results